Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Phase II LUME-Meso study of first-line nintedanib plus chemotherapy in malignant pleural mesothelioma: additional efficacy analyses
Popat S, Novello S, Nowak A, Grosso F, Steele N, Greillier L, John T, Leighl NB, Reck M, Pavlakis N, Sørensen JB, Planchard D, Ceresoli GL, Hughes B, Mazières J, Socinski MA, von Wangenheim U, Barrueco J, Morsli N and Scagliotti G
This poster is presented for scientific education and its content may go beyond the scope of the current market authorization for nintedanib in Canada.
Learn more about the science behind this presentation in the papers and other materials below
Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.
Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: May 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue